Gilead Sciences CAR T Cell Product Tecartus Gets FDA Approval
The U.S. FDA approved Kite - Gilead Sciences (GILD) chimeric antigen receptor (CAR) T cell therapyTecartus™ (brexucabtagene autoleucel). Tecartus has become the first and the only approved CAR T cell therapy for adults with relapsed or refractory mantle cell lymphoma (MCL).
The FDA approval of . . .
This content is for paid subscribers.
Today’s Highlights July 27, 2020